Table 2.
Study schedule at each visit in the clinical trial
| Study schedule | ||||
|---|---|---|---|---|
| Screening | Baseline (visit 1) | 6th week (visit 2) | 12th week (visit 3) | |
| Informed consent form | X | |||
| Recording demographic data | X | |||
| Medical history taking | X | X | ||
| Physical examination a | X | X | X | X |
| Glycemia | X | X | X | X |
| Renal functionb | X | X | X | X |
| Liver functionc | X | X | X | X |
| Thyrotropin-TSH | X | |||
| Lipid profiled | X | X | X | X |
| Fool blood exam-FBEe | X | X | X | |
| Leukocytes formulaf | X | X | X | |
| Electrolytesg | X | X | X | |
| Cardiac/muscular markersh | X | X | X | |
| C-reactive protein | X | X | X | |
| Lipoprotein (a) | X | X | X | |
| Interleukinsi | X | X | X | |
| Inflammatory-miRsj | X | X | X | |
| ECGk | X | X | ||
aWeight, height, waist circumference, and hip circumference
bCreatinine; estimated glomerular filtration rate by CKD-EPI equation
cAspartate aminotransferase glutamic oxaloacetic transaminase (AST/GOT), alanine aminotransferase/ glutamic pyruvic transaminase (ALT/GPT)
dTotal cholesterol, triglyceride, low-density cholesterol (LDL), and high-density cholesterol (HDL)
eWhite blood cells (WBCs), red blood cells (RBCs), hemoglobin, hematocrit, mean cell volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), platelets
fNeutrophils, eosinophils, basophils, lymphocytes, monocytes
gSodium, potassium, chlorine, calcium, phosphorus, magnesium
hCardiac Markers Creatine Kinase (CK)/ myoglobin
iIL6, IL32, IL37, IL38
jmiR-21 and miR-146a
kElectrocardiography